Exploring biomarkers for early detection of pancreatic tumors
A Prospective, Open Large Cohort Study of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Zhejiang University · NCT05433935
This study is trying to find early warning signs in blood, urine, and other samples from patients with a specific type of pancreatic tumor to see if they can help predict when it might turn cancerous.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 0 Years to 90 Years |
| Sex | All |
| Sponsor | Zhejiang University (other) |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05433935 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers that can predict the early carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas. It will involve the prospective enrollment of patients diagnosed with IPMN, who will provide biological samples such as blood, urine, feces, and saliva for analysis. The study focuses on utilizing multi-omics approaches to assess the predictive accuracy of these biomarkers for malignant transformation of IPMN. Secondary endpoints include evaluating surgical resection rates and survival outcomes post-surgery.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals clinically diagnosed with IPMN who do not have other malignant tumors.
Not a fit: Patients with mental disorders affecting cognition or those with serious blood diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of pancreatic tumors, improving patient outcomes.
How similar studies have performed: While there have been studies exploring biomarkers in pancreatic conditions, this specific approach focusing on IPMN and multi-omics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinically diagnosed as IPMN; * without other malignant tumor; * agree to sign informed consent. Exclusion Criteria: * with mental disorders which can affect cognition and cooperation; * with serious blood diseases or taking drugs that can affect peripheral blood
Where this trial is running
Hangzhou, Zhejiang
- the First Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Study coordinator: Tingbo Liang, PhD
- Email: liangtingbo@zju.edu.cn
- Phone: +86 19941463683
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Intraductal Papillary Mucinous Neoplasm, intraductal papillary mucinous neoplasm, biomarkers, prospective cohort